Cramer Is ‘Astonished’ That Chewy Is ‘Doing This Poorly — So Many Of Us Use It’

On CNBC’s "Mad Money Lightning Round," Jim Cramer said yes to The St. Joe Company (NYSE: JOE). "I’ve liked St. Joe forever," he added.

On CNBC’s “Mad Money Lightning Round,” Jim Cramer said yes to The St. Joe Company (NYSE:JOE). “I’ve liked St. Joe forever,” he added.

When asked about Advance Auto Parts, Inc. (NYSE:AAP), he said, “I like to buy best of breed, the best of breed is AutoZone, Inc. (NYSE:AZO).”

Cramer also said he is astonished that Chewy, Inc. (NYSE:CHWY) is “doing this poorly, because so many of us use it.”

Don’t forget to check out our premarket coverage here

“There is now beginning to be a credibility gap between what the company said about the problems with the engines and what’s actually happening,” Cramer said about RTX Corporation (NYSE:RTX). “No bottom yet, not yet, still sells at 15 times earnings, got to go lower.”

The “Mad Money” host said he prefers Chipotle Mexican Grill, Inc. (NYSE:CMG) over CAVA Group, Inc. (NYSE:CAVA).

When asked about Illumina, Inc. (NASDAQ:ILMN), he said, “I don’t think it’s a great company, I think it’s a very good technology business that is not a great company. Danaher Corporation (NYSE:DHR) is the one to buy.”

Price Action: Shares of Danaher gained 1.7% to close at $252.45, while Illumina gained 0.2% to $150.77 on Wednesday. CAVA shares fell 1% to settle at $35.64, while Chipotle closed at $1,933.04 on Wednesday. RTX shares settled at $75.56, while Chewy fell 1.8% to close at $21.51 on Wednesday. AutoZone shares gained 0.2% to $2,531.04, while Advance Auto Parts gained 0.8% to $57.93. St. Joe Company shares declined 2.9% to close at $57.60 on Wednesday.

Now Read This: Top 5 Tech And Telecom Stocks You May Want To Dump In Q3

Total
0
Shares
Related Posts
Read More

Fortress Biotech Subsidiary Helocyte Announces Option Agreement With City Of Hope For Exclusive Worldwide Rights To Use A Novel Bispecific CMV/HIV CAR T Cell Therapy For Treatment Of Adults Living With HIV-1

Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been

FBIO